People with schizophrenia die 15‐20 years prematurely. Understanding mortality risk and
aggravating/attenuating factors is essential to reduce this gap. We conducted a systematic …

Objectives: To provide guidance for the management of mood disorders, based on scientific
evidence supplemented by expert clinical consensus and formulate recommendations to …

Importance It has remained unclear whether there are clinically meaningful differences
between antipsychotic treatments with regard to preventing relapse of schizophrenia, owing …

Importance The effectiveness of antipsychotic polypharmacy in schizophrenia relapse
prevention is controversial, and use of multiple agents is generally believed to impair …

People with severe mental illness have a considerably shorter lifespan than the general
population. This excess mortality is mainly due to physical illness. Next to mental illness …

Introduction It has remained controversial if antipsychotic treatment is associated with
increased or decreased mortality among patients with schizophrenia, and if there are any …

Objective Polypharmacy has been linked to a myriad of adverse consequences, and
escalating rates of polypharmacy present an emerging concern, particularly among older …

Das Kompendium der Psychiatrischen Pharmakotherapie liegt jetzt in der 14. Auflage vor.
Es ist in der Nachfolge der Psychiatrischen Pharmakotherapie, die von 1974–1996 in …

BackgroundNumerous treatment guidelines recommend that long-term use of
benzodiazepines (BZD) should be avoided primarily due to development of tolerance and a …

Background Because of ageing populations, the growth in the number of people with multi-
morbidity and greater compliance with disease-specific guidelines, polypharmacy is …